INTRODUCTION: A number of staging systems have been proposed for malignant pleural mesothelioma (MPM) in the past, but few have utilized a TNM (tumor, node, metastasis) system. The International Association for the Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG) previously developed a TNM-staging system which has been accepted by the International Union Against Cancer (UICC) and the American Joint Commission on Cancer (AJCC). The present study examines this staging system by analysing the updated IASLC database for patients with MPM. METHODS: De-identified data from participating centres dated from 1995 to 2009 were submitted to the IASLC Statistical Center. Surgical procedures included those with a curative or palliative intent. Survival was measured from the date of pathologic diagnosis to the most recent contact or death. Endpoints included overall survival and analysis of potential prognostic factors. RESULTS: Data was available for 3,101 patients from 15 centers, mostly from North America and Europe. After a median follow-up of 15 months, a number of clinicopathological and treatment-related prognostic factors were found to significantly influence overall survival. These included overall tumor stage based on the proposed TNM staging system, T category, N category, tumor histology, gender, age, and type of operation. CONCLUSIONS: The IASLC database represents the largest, multicenter and international database on MPM to date. Analyses demonstrate that the proposed TNM staging system effectively distinguishes the T and N categories, but also highlight areas for potential revision in the future.
INTRODUCTION: A number of staging systems have been proposed for malignant pleural mesothelioma (MPM) in the past, but few have utilized a TNM (tumor, node, metastasis) system. The International Association for the Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG) previously developed a TNM-staging system which has been accepted by the International Union Against Cancer (UICC) and the American Joint Commission on Cancer (AJCC). The present study examines this staging system by analysing the updated IASLC database for patients with MPM. METHODS: De-identified data from participating centres dated from 1995 to 2009 were submitted to the IASLC Statistical Center. Surgical procedures included those with a curative or palliative intent. Survival was measured from the date of pathologic diagnosis to the most recent contact or death. Endpoints included overall survival and analysis of potential prognostic factors. RESULTS: Data was available for 3,101 patients from 15 centers, mostly from North America and Europe. After a median follow-up of 15 months, a number of clinicopathological and treatment-related prognostic factors were found to significantly influence overall survival. These included overall tumor stage based on the proposed TNM staging system, T category, N category, tumor histology, gender, age, and type of operation. CONCLUSIONS: The IASLC database represents the largest, multicenter and international database on MPM to date. Analyses demonstrate that the proposed TNM staging system effectively distinguishes the T and N categories, but also highlight areas for potential revision in the future.
Authors: Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk Journal: Lancet Oncol Date: 2011-11 Impact factor: 41.316
Authors: Apostolos Nakas; Edward Black; James Entwisle; Salli Muller; David A Waller Journal: Eur J Cardiothorac Surg Date: 2010-02-06 Impact factor: 4.191
Authors: Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori Journal: Lung Cancer Date: 2007-04-02 Impact factor: 5.705
Authors: Tristan D Yan; Michael Boyer; Mo Mo Tin; Daniel Wong; Catherine Kennedy; Jocelyn McLean; Paul G Bannon; Brian C McCaughan Journal: J Thorac Cardiovasc Surg Date: 2009-03-09 Impact factor: 5.209
Authors: Clemens Aigner; Mir Ali Reza Hoda; Gyoergy Lang; Shahrokh Taghavi; Gabriel Marta; Walter Klepetko Journal: Eur J Cardiothorac Surg Date: 2008-04-14 Impact factor: 4.191
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer Journal: J Thorac Dis Date: 2013-08 Impact factor: 2.895
Authors: Wickii T Vigneswaran; Diana Y Kircheva; Adrian E Rodrigues; Sydeaka Watson; Amy Durkin Celauro; Berkley Rose; Hedy L Kindler; Aliya N Husain Journal: World J Surg Date: 2018-04 Impact factor: 3.352
Authors: David A Mahvi; Rong Liu; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut Journal: CA Cancer J Clin Date: 2018-10-17 Impact factor: 508.702
Authors: Ritu R Gill; David P Naidich; Alan Mitchell; Michelle Ginsberg; Jeremy Erasmus; Samuel G Armato; Christopher Straus; Sharyn Katz; Demetrois Patios; William G Richards; Valerie W Rusch Journal: J Thorac Oncol Date: 2016-05-12 Impact factor: 15.609
Authors: G L Ceresoli; F Grosso; P A Zucali; M Mencoboni; G Pasello; C Ripa; D Degiovanni; M Simonelli; A Bruzzone; C Dipietrantonj; E Piccolini; G D Beretta; A G Favaretto; L Giordano; A Santoro; M Botta Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640